地西他滨联合常规化疗方案治疗急性白血病合并T/NK细胞淋巴瘤的效果分析  

Analysis of the Effect of Decitabine Combined with Chemotherapy Regimen for the Treatment of Acute Leukemia with T/NK Cell Lymphoma

作　　者：刘晓[1] 李巍[1] 傅云峰[2] 吴雪琴[1] 秦兰[1] LIU Xiao;LI Wei;FU Yunfeng;WU Xueqin;QIN Lan(Hematology Department of the Fourth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, 830000, China;Department of Blood Transfusion of the Third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China)

机构地区：[1]新疆医科大学第四附属医院血液科,新疆乌鲁木齐830000 [2]中南大学湘雅三医院输血科,湖南长沙410013

出　　处：《肿瘤药学》2018年第2期184-187,共4页Anti-Tumor Pharmacy

基　　金：国家自然科学基金资助项目(81101648)

摘　　要：目的探讨地西他滨联合常规化疗方案治疗急性白血病合并T/NK细胞淋巴瘤的治疗效果及对患者凝血指标的影响。方法选取我院收治的急性白血病合并T/NK细胞淋巴瘤患者40例,按照随机数字法分为对照组(n=20)和研究组(n=20),对照组应用常规化疗方案进行治疗,研究组在对照组的基础上联合地西他滨治疗。观察两组患者的临床治疗效果、不良反应以及治疗前后凝血功能指标的变化。结果研究组患者近期疗效明显优于对照组(P<0.05);研究组患者感染、恶心呕吐、骨髓抑制等非血液学不良反应的发生率明显低于对照组(P<0.05);研究组患者外周白细胞及血小板计数减少量明显低于对照组,并且血液学感染的发生率明显低于对照组(P<0.05);治疗前,两组患者的凝血功能指标无明显差异(P>0.05),治疗后,研究组患者PT、APTT、FIB、TT等凝血功能指标的改善情况明显优于对照组(P<0.05)。结论应用地西他滨联合常规化疗方案治疗急性白血病合并T/NK细胞淋巴瘤,可降低患者血液学及非血液学不良反应的发生率,明显改善患者的凝血功能,提高患者的生活质量,整体治疗效果较为理想,临床上可进一步推广应用。Objective To investigate the effect of decitabine combined with chemotherapy in the treatment of acute leukemia and T/NK cell lymphoma. Methods A total of 40 cases of acute leukemia patients with T/NK cell lymphoma in our hospital were randomly divided into control group （n=20） and research group （n=20）. Patients in the control group got chemotherapy, while those in the research group were treated with decitabine plus chemotherapy. The clinical effects, adverse reactions, hematological indexes, adverse reactions and improvement of coagulation function were observed and compared between the two groups. Results Patients in the research group had better therapeutic effects than those in the control group （P〈0.05）. The research group had significantly lower incidence of non hematologic adverse reactions such as infection, nausea and vomiting, bone marrow suppression than the control group （P〈0.05）. In addition, the decrease of peripheral white blood cells and platelet count in the research group was significantly less than that of the control group, and blood infection rate of the research group was also significantly lower than that of the control group （P〈0.05）. For the blood coagulation index, there was no significant difference between the two groups before treatment （P〉0.05）. However, after treatment, the improvement in blood coagulation indexes such as PT, APTT, FIB and TT in the research group was superior to that of the control group （P〈0.05）. Conclusion The treatment of decitabine combined with chemotherapy had good treatment effect on patients with acute leukemia complicated with T/NK cell lymphoma. It could re-duce the incidence of hematologic and non hematologic adverse reactions, improve the coagulation function and the quality of life of patients. It could be further applied in clinic.

关 键 词：地西他滨 化疗方案 急性白血病 合并T/NK细胞淋巴瘤 治疗效果 凝血指标 

分 类 号：R733.7[医药卫生—肿瘤]